IL-1 Receptor Antagonist to Prevent Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04205838

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-25T22:28:19.941799+00:00

Published At

2026-02-27T00:00:00+00:00

Record Updated At

2026-02-27

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma", "Progressive Disease", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent High Grade B-Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory High Grade B-Cell Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma", "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2026-02-27"

protocolSection.identificationModule.nctId

"NCT04205838"

protocolSection.identificationModule.officialTitle

"IL-1 Receptor Antagonist to Prevent Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome"

protocolSection.statusModule.overallStatus

"TERMINATED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Diffuse Large B-Cell Lymphoma, Not Otherwise Specified (protocolSection.conditionsModule.conditions)
• High Grade B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Progressive Disease (protocolSection.conditionsModule.conditions)
• Recurrent Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent High Grade B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory High Grade B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.